CLINICAL_TRIALS
trial_result
· 2024-09-27
Clinical Trial Update: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma [Phase 1]
Summary
Phase 1 results update for elranatamab (PF-06863135) in Japanese participants with relapsed or refractory multiple myeloma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2024-09-27